Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
about
Clinical utility of eslicarbazepine: current evidence.Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.Simultaneous UPLC-MS/MS determination of antiepileptic agents for dose adjustment.Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures.Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.[Anticonvulsant add-on therapy with Eslicarbazepine acetate : Results of the EPOS-study in adults in Germany].Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence.Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.Oxcarbazepine-induced cytotoxicity and genotoxicity in human lymphocyte cultures with or without metabolic activation.Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study.
P2860
Q35087964-A2B0E5CA-53E8-4D4B-A2CB-ACBCC519ED96Q35664957-A59EB963-27F9-445A-B723-29115ABE13DFQ36225438-7C0DF9A1-C988-4CBE-A610-B5ABD8CED973Q37680030-A9C782C0-D869-4E85-81BB-5D8ED7D682CCQ38223958-2C2B3315-D293-43D7-BBB9-7E4BE602FF96Q38644163-F1E66D5A-2435-4531-9D19-EC7D5BF2DEADQ38656011-12048088-C813-49F8-9F05-8260D07A1FAFQ39456360-ECC336A2-0589-4E52-92C2-C340DDF4FC4BQ40611807-AD798333-455A-4750-B2B6-894E034CAADAQ47235722-0EB12C23-BC9F-4186-9FA2-55242BF19983Q47797132-DF22912C-CC98-4C84-AC7D-34EEF749C2FBQ48424510-AA6958DE-6A4D-4040-B4AE-0A80594AFABEQ52811670-075B55D3-AF1D-493C-AEB4-86CE932AE691Q53057610-32008709-8A6B-4548-A00F-9AC19BBE7795
P2860
Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Pharmacokinetics and tolerabil ...... y state in healthy volunteers.
@en
Pharmacokinetics and tolerabil ...... y state in healthy volunteers.
@nl
type
label
Pharmacokinetics and tolerabil ...... y state in healthy volunteers.
@en
Pharmacokinetics and tolerabil ...... y state in healthy volunteers.
@nl
prefLabel
Pharmacokinetics and tolerabil ...... y state in healthy volunteers.
@en
Pharmacokinetics and tolerabil ...... y state in healthy volunteers.
@nl
P2093
P2860
P50
P356
P1433
P1476
Pharmacokinetics and tolerabil ...... y state in healthy volunteers.
@en
P2093
Christian Elger
Manuel Vaz-da-Silva
Meir Bialer
Teresa Nunes
P2860
P304
P356
10.1111/EPI.12242
P577
2013-06-12T00:00:00Z